Universal Health Realty Income Trust (UHT) Q2 2024 earnings summary

Executive summary

• Net income for Q2 2024 was $5.3 million ($0.38 per diluted share), up from $3.5 million ($0.25 per diluted share) in Q2 2023, driven by reduced expenses and increased property income, partially offset by higher interest expense.

• For the first six months of 2024, net income was $10.6 million ($0.76 per diluted share), compared to $7.9 million ($0.57 per diluted share) in the same period of 2023.

• Revenues for Q2 2024 rose 3.9% year-over-year to $24.7 million, with growth from new and existing properties.

• Funds from operations (FFO) for Q2 2024 increased to $12.4 million ($0.90 per diluted share) from $10.6 million ($0.77 per diluted share) in Q2 2023.

• FFO for the first six months of 2024 was $24.8 million ($1.79 per diluted share), up from $22.0 million ($1.59 per diluted share) in the same period of 2023.

Financial highlights

• Q2 2024 revenues: $24.7 million (Q2 2023: $23.8 million); H1 2024: $49.9 million (H1 2023: $47.0 million).

• Q2 2024 lease revenue from UHS facilities was $8.5 million, and from non-related parties $14.4 million.

• Q2 2024 FFO per diluted share: $0.90 (Q2 2023: $0.77); H1 2024: $1.79 (H1 2023: $1.59).

• Dividend paid per share in Q2 2024 was $0.73, totaling $10.1 million; H1 2024: $1.455 per share.

• Depreciation and amortization expense for Q2 2024 was $6.8 million.

Outlook and guidance

• Management expects sufficient capital resources for the next twelve months, including REIT distribution requirements.

• No acquisitions or divestitures occurred in H1 2024; focus remains on internal growth and capital allocation.

• Interest rate environment, inflationary pressures, staffing shortages, and regulatory changes remain key concerns for future performance.

• Forward-looking statements caution that future results may differ materially due to factors beyond management's control.